Neurocrine shareholders approve equity plan amendments, elect directors at 2022 annual meeting

NEUROCRINE BIOSCIENCES INC

Three Class II directors elected: Richard Pops, Shalini Sharp, Stephen Sherwin; each received >72M votes.
Advisory vote on executive compensation passed with 92.76% support.
Amended and restated 2020 Equity Incentive Plan and ESPP approved (89% and 99.6% of votes cast, respectively).
Ernst & Young LLP ratified as independent auditor for fiscal 2022 with 93.28% approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.